Completed PHASE3 INTERVENTIONAL 2-arm NCT02578680

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

Sponsor: Merck Sharp & Dohme LLC

Conditions Non-Small-Cell Lung Carcinoma

Interventions Carboplatin Cisplatin Dexamethasone 4 mg Folic acid 350-1000 μg Pembrolizumab 200 mg Pemetrexed Saline solution Vitamin B12 1000 μg

Updated 23 times since 2017 Last updated: Sep 5, 2024 Started: Jan 15, 2016 Primary completion: Nov 8, 2017 Completion: Jun 22, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non-Small-Cell Lung Carcinoma and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 23 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

23 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE3
Sep 2024 — Oct 2024 [monthly]

Completed PHASE3
Aug 2024 — Sep 2024 [monthly]

Completed PHASE3
Jul 2024 — Aug 2024 [monthly]

Completed PHASE3
Aug 2023 — Jul 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed

▶ Show 18 earlier versions

Jun 2023 — Aug 2023 [monthly]

Active Not Recruiting PHASE3
Feb 2023 — Jun 2023 [monthly]

Active Not Recruiting PHASE3
Sep 2022 — Feb 2023 [monthly]

Active Not Recruiting PHASE3
Jun 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE3
Apr 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Apr 2022 [monthly]

Active Not Recruiting PHASE3
Nov 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Feb 2020 — Nov 2020 [monthly]

Active Not Recruiting PHASE3
Apr 2019 — Feb 2020 [monthly]

Active Not Recruiting PHASE3
Dec 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE3
Apr 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Mar 2018 — Apr 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Dec 2017 — Mar 2018 [monthly]

Recruiting PHASE3

Status: Active Not Recruiting → Recruiting
Jun 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE3
Mar 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.